Compare · DRAD vs MDT
DRAD vs MDT
Side-by-side comparison of Digirad Corporation (DRAD) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRAD and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT carries a market cap of $116.35B.
- MDT has hit the wire 13 times in the past 4 weeks while DRAD has been quiet.
- MDT has more recent analyst coverage (25 ratings vs 0 for DRAD).
- Company
- Digirad Corporation
- Medtronic plc.
- Price
- -
- $90.96-0.74%
- Market cap
- -
- $116.35B
- 1M return
- -
- +0.22%
- 1Y return
- -
- -3.29%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 0
- 13
- Recent ratings
- 0
- 25
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest DRAD
- SEC Form 8 filed
- Digirad Corporation to Present at Investor Conferences in November
- Digirad Corporation Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2020
- Digirad Corporation to Release Third Quarter 2020 Financial Results on November 13
- Digirad Corporation to Sell DMS Health for $18.75 Million
Latest MDT
- Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
- Medtronic executives to speak at upcoming investor conferences
- SEC Form 10-Q filed by Medtronic plc.
- SEC Form IRANNOTICE filed by Medtronic plc.
- Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance
- Medtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery
- Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR
- Needham reiterated coverage on Medtronic with a new price target
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 1,084 units of Ordinary Shares, decreasing direct ownership by 0.92% to 116,336 units (SEC Form 4)